🔗 Share this article

As America proceeds with historic adjustments to its immunization schedules, a particular individual has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based sports physician and public health researcher who first made her name by questioning Covid vaccinations in the global health crisis and has zeroed in on alleged fatalities after Covid vaccination in her brief time at the FDA.

Proposed Shifts to Childhood Immunization Schedule

Health officials planned to reveal major changes to the pediatric vaccine schedule in December, bringing the US with Denmark’s immunization schedule, sources say – a substantial departure that would put the US at odds with many the international standard with insufficient data for improved outcomes. The announcement has been pushed back until the next year.

Instead of Vinay Prasad, Høeg is set to present at the event. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the division this calendar year.

A Shift at the FDA

This interim role could signify a tighter collaboration between the pharmaceutical and vaccine divisions as Høeg and Prasad strengthen their influence at the FDA – and it signals a increased emphasis upon reevaluating already-approved vaccines at the FDA.

Dr. Høeg has repeatedly called for halting specific childhood vaccine recommendations in the US so as to align more like Denmark, a society with comprehensive healthcare and a population approximately the size of the state of Wisconsin.

To date comments, she has continued to focus on immunizations – usually the domain of Prasad, head of the FDA’s CBER – instead of medication approval.

Doubts Over Qualifications

Høeg has no obvious experience in drug development, approval processes or management, which has been standard for previous leaders of the Center for Biologics Evaluation and Research. She has worked at the FDA as a top consultant to the FDA chief and the vaccine center since March.

“It seems she lacks to have the requisite experience” for leading the drug-regulation department, remarked Jonathan Howard. “She has not conducted a scientific study. She is not versed in running a sizeable institution. She has no expertise in industry regulation.”

Former directors of the center would “understand regulatory frameworks and the science of medication creation”, noted Dr. Janet Woodcock. “Clearly, she doesn’t have the kind of background that former directors who headed the center have had.”

The drug center has an enormous portfolio at the agency, the former commissioner emphasized.

“Everybody just focuses on the new drug program, but the generic program approves thousands of off-brand pharmaceuticals. There’s a biologic copycat branch, OTC medication office and more, and all of those have to be managed,” she explained. “The responsibility you neglect, that is precisely what that I always told people is going to cause problems.”

Furthermore, a significant administrative element to the job, which supervises in excess of 5,000 staff members. “It’s a enormous management job, if you execute it properly,” the former official concluded.

Official Statement and Disputed Policies

In response to concerns about Dr. Høeg's qualifications and whether this selection indicates more teamwork among FDA leaders on immunizations, a representative stated that the “concerns stem from incorrect premises”.

“This background is consistent with the responsibilities of her job,” the representative stated, pointing to the period Høeg spent counseling the agency head on “pharmaceutical safety and approval science, including computerized risk analysis and shot safety tracking”.

As the temporary head, Dr. Høeg inherits the commissioner’s controversial fast-track approval initiative, a disputed expedited therapy clearance system that allegedly troubled her former heads. “By what process are these medications being picked for this fast-track system? Who takes the calls?” Howard questioned. “There is a lot of confidentiality occurring at the regulatory body right now.”

Overall, he stated, “the FDA looks to be trending towards less stringent oversight of most medications, except for shots.”

Public Track Record on Immunizations

Concerning immunizations, Høeg has a more documented, if concerning, past, Howard said. She authored a study using unverified public submissions to estimate the rate of myocarditis after Covid vaccination. She counseled the Florida chief medical officer Dr. Joseph Ladapo, who was said to have altered data to imply COVID-19 vaccines are riskier than they are.

Included in her “wish list” for the current government encompassed changing rules for recently developed shots and discontinuing “non-essential” vaccines, she remarked post-election on a online show. At the FDA, Høeg has according to sources floated the idea of preventing teenage boys from obtaining COVID-19 vaccinations.

“She’s an all-around true believer who commences with her preconceived notions and reverse-engineers to accommodate the data in a highly disingenuous, untruthful manner,” Dr. Howard stated.

Consolidating Power and a “Revenge Tour”

Høeg aligned with fellow skeptics, {like|